Organisation: WTO

IAM talked with Petro Terblanche, CEO of Afrigen Biologics, about the WHO vaccine hub and its IP strategy

21 February 2024

Practitioners should carefully consider how the term is being translated at the Chinese courts and ensure that different approaches do not facilitate unintended outcomes

31 January 2024

In the week that the European Commission’s proposed SEP policy faces a crucial vote, WiseHarbor founder Keith Mallinson analyses the risks of taking an aggregate-based approach

23 January 2024

Only the parties’ Chinese counsel have been allowed access to the unredacted version of the ruling

15 January 2024

On the face of it the pilot provides a simple fast-track channel for applicants operating in the semiconductor field. However, there are some quirks in the rules which need to be considered

04 January 2024

Disappointment with last year’s WTO agreement on suspending patent rights to secure covid-19 vaccine supplies has led campaigners to intensify calls for a new agreement that would include know-how

05 October 2023

Kathi Vidal and Chris Coons clearly see standards as a pivotal issue and have made no secret of their concerns about the proposed EU SEP licensing regulation, but they are constrained in how far and how quickly they can act

03 August 2023

Saturday Opinion: Disseminating covid diagnostics and therapeutics is critical, but attempting to do so via the TRIPS waiver extension is rife with unintended consequences

04 March 2023

Saturday Opinion: Supporting the legality of fair non-compete agreements will enhance foreign investors’ reasonable expectations of protection by the US IP system

28 January 2023

IAM looks back at the most important pharmaceuticals developments of the past 12 months

28 December 2022